Unum Therapeutics Inc (UMRX):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Unum Therapeutics Inc (UMRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8122)・商品コード:DATA904C8122
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:37
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Unum Therapeutics Inc (Unum Therapeutics) is a clinical-stage bio-pharmaceutical company focused on the development and commercialization of novel antibody-coupled cellular immunotherapies to fight cancers. Its pipeline product portfolio include ACTR087 + rituximab, a CD20 targeting chimeric monoclonal antibody to treat non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia; ACTR707 + rituximab as well as ACTR707 + Trastuzumab for the treatment of HER2+ cancers; ACTR087 + SEA-BCMA against multiple myeloma. The company uses its proprietary Antibody-Coupled T-cell Receptor (ACTR) technology in combination of tumor-targeting antibodies which direct individual cytotoxic T-lymphocytes (CTLs) to activate the body’s own immune system to fight hematologic and solid tumor cancers. The company seeks to works in partnership with other biotechnology companies to develop new combinations of ACTR T-cells and tumor targeting antibodies. Unum Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Unum Therapeutics Inc (UMRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Unum Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Unum Therapeutics Raises USD65 Million in Series B Financing 11
Unum Therapeutics Raises USD12 Million in Series A Venture Financing 13
Licensing Agreements 14
Seattle Genetics Enters into Licensing Agreement with Unum Therapeutics 14
Unum Therapeutics Expands Licensing Agreement with National University of Singapore and St. Jude Children’s Research Hospital 15
Equity Offering 17
Unum Therapeutics Raises USD69.2 Million in IPO 17
Unum Therapeutics Raises USD5 Million in Private Placement of Shares 19
Unum Therapeutics Inc – Key Competitors 20
Unum Therapeutics Inc – Key Employees 21
Unum Therapeutics Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Aug 13, 2018: Unum Therapeutics reports second quarter 2018 financial results and provides business update 23
May 14, 2018: Unum Therapeutics Announces First Quarter 2018 Financial Results 25
Research And Development 27
Apr 03, 2017: Unum Therapeutics to present new data on ACTR platform at AACR 2017 27
Corporate Communications 28
Mar 02, 2018: Unum Therapeutics Appoints Karen J. Ferrante And Robert J. Perez As Board Directors 28
Mar 02, 2018: Unum Therapeutics Announces Names Christiana Stamoulis To Additional Role Of President 29
Product News 30
10/27/2017: Unum Therapeutics to Present New Data on its Antibody-Coupled T Cell Receptor Platform at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 30
05/09/2017: Unum Therapeutics to Present Data on its Antibody-Coupled T Cell Receptor Platform at the Upcoming Annual Meeting of the American Society of Gene & Cell Therapy 31
Product Approvals 32
Aug 23, 2017: Unum Therapeutics Announces Active Investigational New Drug Application for ACTR087 in Combination with SEA-BCMA in Patients with Relapsed/Refractory Multiple Myeloma 32
Clinical Trials 33
Jul 12, 2018: Unum Therapeutics to Present Pre-Clinical Data on its Antibody-Coupled T Cell Receptor (ACTR) Platform at the American Society of Hematology (ASH) Summit on Emerging Immunotherapies for Hematological Diseases 33
Nov 01, 2017: Unum Therapeutics Announces Presentation of Initial Clinical Data from the ATTCK-20-2 Trial and Pre-Clinical Data on its Antibody-Coupled T Cell Receptor Platform at the Upcoming 59th American Society of Hematology (ASH) Annual Meeting 34
Jun 19, 2017: Unum Therapeutics Announces Active Investigational New Drug Application for ACTR707 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Lymphoma 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Unum Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Unum Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Unum Therapeutics Raises USD65 Million in Series B Financing 11
Unum Therapeutics Raises USD12 Million in Series A Venture Financing 13
Seattle Genetics Enters into Licensing Agreement with Unum Therapeutics 14
Unum Therapeutics Expands Licensing Agreement with National University of Singapore and St. Jude Children’s Research Hospital 15
Unum Therapeutics Raises USD69.2 Million in IPO 17
Unum Therapeutics Raises USD5 Million in Private Placement of Shares 19
Unum Therapeutics Inc, Key Competitors 20
Unum Therapeutics Inc, Key Employees 21

List of Figures
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Unum Therapeutics Inc (UMRX):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8122)販売に関する免責事項を必ずご確認ください。
★調査レポート[Unum Therapeutics Inc (UMRX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆